Kim Coghill

CV Therapeutics Inc. initiated a pivotal Phase III trial for CVT-3146, a candidate for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (BioWorld Today)

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

Oct. 30, 2003

By Kim Coghill

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

Oct. 30, 2003

By Kim Coghill

CV Therapeutics Starts Phase III For CVT-3146, Waits On Ranexa

Oct. 30, 2003

By Kim Coghill

CV Therapeutics Inc. initiated a pivotal Phase III trial for CVT-3146, a candidate for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (BioWorld Today)

Kim Coghill

ARTICLES

Telik Raises $130M To Support Telcyta, Telintra Clinical Trials

As Entereg Nears Filing, Adolor Raises $103.5M Via Public Sale

FDA Backs Cloned Livestock, Suggests More Data Prudent

FDA Backs Cloned Livestock, Suggests More Data Prudent

Hollis-Eden Reports Preliminary Miss With HE2200 In Cholesterol

Hollis-Eden Reports Preliminary Miss With HE2200 In Cholesterol

CV Therapeutics Starts Phase III For CVT-3146, Waits On Ranexa

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

CV Therapeutics Starts Phase III For CVT-3146, Waits On Ranexa

Today's news in brief

FENS 2026: Shedding light on the sheddome

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

FENS 2026: Next-gen biologics take on brain disease

Recombinant vaccine inhibits HBV-associated HCC growth